Shares of uniQure N.V. (NASDAQ:QURE – Get Free Report) gapped up prior to trading on Thursday. The stock had previously closed at $22.69, but opened at $23.40. uniQure shares last traded at $23.2250, with a volume of 541,222 shares traded.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on QURE. Weiss Ratings raised shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Royal Bank Of Canada lowered their price objective on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, October 2nd. Barclays downgraded uniQure from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $60.00 to $28.00 in a research report on Monday, October 5th. HC Wainwright reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, September 29th. Finally, Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average target price of $53.25.
Read Our Latest Stock Report on uniQure
uniQure Trading Down 2.9%
The firm’s 50-day simple moving average is $36.88 and its 200-day simple moving average is $34.02. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.56 billion, a PE ratio of -5.59 and a beta of 1.06.
uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business posted ($0.69) earnings per share. Equities analysts expect that uniQure N.V. will post -3.82 earnings per share for the current year.
Hedge Funds Weigh In On uniQure
A number of large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC raised its stake in shares of uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the last quarter. Two Seas Capital LP purchased a new stake in shares of uniQure during the third quarter worth about $31,988,000. Siren L.L.C. purchased a new stake in shares of uniQure during the first quarter worth about $16,350,000. SG Americas Securities LLC grew its stake in shares of uniQure by 1,107.3% in the first quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company’s stock worth $12,697,000 after purchasing an additional 712,278 shares during the last quarter. Finally, Maverick Capital Ltd. grew its stake in shares of uniQure by 5.4% in the first quarter. Maverick Capital Ltd. now owns 697,640 shares of the biotechnology company’s stock worth $11,406,000 after purchasing an additional 35,820 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.
About uniQure
uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.
uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.
Further Reading
- Five stocks we like better than uniQure
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
